A Transformative Breakthrough
A tested, proprietary chemistry platform that cuts costs and improves product performance in a growth industry
Corporate Profile : Summary
​
-
We design, build and sell proprietary Point-of-Care (PoC) diagnostic products for respiratory diseases
-
Our PoC diagnostics and results are conducted at the location of patient sample collection
-
Gemina advances are a 'quantum leap' in Lateral Flow Assays
-
We aim to democratize diagnostics, bringing the reality of precision diagnostics to every health system in the world. Providing lab accuracy in affordable formats to doctors, health professionals, clinics and homes in every part of the globe
The Gemina Board
John Davies
Independent Chairman
Bola Grace
Independent Director
Brian Firth
Chief Executive Officer
Rob Greene
Chief Technology Officer
Martin Cronin
Independent Director
Martha Najib
Independent Director
Gemina Labs News
Stay in touch with the latest news from Gemina Labs:
Corporate and Regulatory News is released to the press via Accesswire and can be accessed via mainstream finance news services such as Yahoo Finance.
​
Our own news page is where you'll find corporate and regulatory news, appointments, organisation & people, operations and product news.
​
You'll also find us on LinkedIn.
Financial Calendar
31 May 2023
Year End (31st January) Results published
30 June 2023
Q1 (30th April) Results published
30 September 2023
Q2 (31st July) Results published
31 December 2023
Q3 (31st October) Results published
31 May 2024
Year End (31st January) Results published